Serology assessment of antibody response to SARS-CoV-2 in patients with COVID-19 by rapid IgM/IgG antibody test
(2020) In Infection Ecology and Epidemiology 10(1).- Abstract
The coronavirus disease 2019 (COVID-19) pandemic has created a global health- and economic crisis. Detection of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which causes COVID-19 by serological methods is important to diagnose a current or resolved infection. In this study, we applied a rapid COVID-19 IgM/IgG antibody test and performed serology assessment of antibody response to SARS-CoV-2. In PCR-confirmed COVID-19 patients (n = 45), the total antibody detection rate is 92% in hospitalized patients and 79% in non-hospitalized patients. The total IgM and IgG detection is 63% in patients with <2 weeks from disease onset; 85% in non-hospitalized patients with >2 weeks disease duration; and 91% in... (More)
The coronavirus disease 2019 (COVID-19) pandemic has created a global health- and economic crisis. Detection of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which causes COVID-19 by serological methods is important to diagnose a current or resolved infection. In this study, we applied a rapid COVID-19 IgM/IgG antibody test and performed serology assessment of antibody response to SARS-CoV-2. In PCR-confirmed COVID-19 patients (n = 45), the total antibody detection rate is 92% in hospitalized patients and 79% in non-hospitalized patients. The total IgM and IgG detection is 63% in patients with <2 weeks from disease onset; 85% in non-hospitalized patients with >2 weeks disease duration; and 91% in hospitalized patients with >2 weeks disease duration. We also compared different blood sample types and suggest a higher sensitivity by serum/plasma over whole blood. Test specificity was determined to be 97% on 69 sera/plasma samples collected between 2016-2018. Our study provides a comprehensive validation of the rapid COVID-19 IgM/IgG serology test, and mapped antibody detection patterns in association with disease progress and hospitalization. Our results support that the rapid COVID-19 IgM/IgG test may be applied to assess the COVID-19 status both at the individual and at a population level.
(Less)
- author
- organization
-
- Translational Muscle Research (research group)
- EXODIAB: Excellence of Diabetes Research in Sweden
- Infection Medicine (BMC)
- Translational infection medicine (research group)
- Clinical Chemistry, Malmö (research group)
- Division of Clinical Chemistry and Pharmacology
- LUBIN Lab- Lund Brain Injury laboratory for Neurosurgical research (research group)
- Cardiovascular Research - Translational Studies (research group)
- publishing date
- 2020
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- antibody test, COVID-19, disease severity and duration, IgM and IgG, SARS-CoV-2, serology assessment
- in
- Infection Ecology and Epidemiology
- volume
- 10
- issue
- 1
- article number
- 1821513
- publisher
- Taylor & Francis
- external identifiers
-
- pmid:33062217
- scopus:85091301104
- ISSN
- 2000-8686
- DOI
- 10.1080/20008686.2020.1821513
- project
- Serology assessment of antibody response to SARS-CoV-2 in patients with COVID-19 by rapid IgM/IgG antibody test
- language
- English
- LU publication?
- yes
- id
- 7881faa4-20c3-47dc-896b-90bbaef63760
- date added to LUP
- 2020-11-03 11:58:30
- date last changed
- 2024-03-20 17:54:36
@article{7881faa4-20c3-47dc-896b-90bbaef63760, abstract = {{<p>The coronavirus disease 2019 (COVID-19) pandemic has created a global health- and economic crisis. Detection of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which causes COVID-19 by serological methods is important to diagnose a current or resolved infection. In this study, we applied a rapid COVID-19 IgM/IgG antibody test and performed serology assessment of antibody response to SARS-CoV-2. In PCR-confirmed COVID-19 patients (n = 45), the total antibody detection rate is 92% in hospitalized patients and 79% in non-hospitalized patients. The total IgM and IgG detection is 63% in patients with <2 weeks from disease onset; 85% in non-hospitalized patients with >2 weeks disease duration; and 91% in hospitalized patients with >2 weeks disease duration. We also compared different blood sample types and suggest a higher sensitivity by serum/plasma over whole blood. Test specificity was determined to be 97% on 69 sera/plasma samples collected between 2016-2018. Our study provides a comprehensive validation of the rapid COVID-19 IgM/IgG serology test, and mapped antibody detection patterns in association with disease progress and hospitalization. Our results support that the rapid COVID-19 IgM/IgG test may be applied to assess the COVID-19 status both at the individual and at a population level.</p>}}, author = {{De Marinis, Yang and Sunnerhagen, Torgny and Bompada, Pradeep and Bläckberg, Anna and Yang, Runtao and Svensson, Joel and Ekström, Ola and Eriksson, Karl Fredrik and Hansson, Ola and Groop, Leif and Gonçalves, Isabel and Rasmussen, Magnus}}, issn = {{2000-8686}}, keywords = {{antibody test; COVID-19; disease severity and duration; IgM and IgG; SARS-CoV-2; serology assessment}}, language = {{eng}}, number = {{1}}, publisher = {{Taylor & Francis}}, series = {{Infection Ecology and Epidemiology}}, title = {{Serology assessment of antibody response to SARS-CoV-2 in patients with COVID-19 by rapid IgM/IgG antibody test}}, url = {{https://lup.lub.lu.se/search/files/119180326/Serology_assessment_of_antibody_response_to_SARS_CoV_2_in_patients_with_COVID_19_by_rapid_IgM_IgG_antibody_test.pdf}}, doi = {{10.1080/20008686.2020.1821513}}, volume = {{10}}, year = {{2020}}, }